Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio.

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that that fell short of analyst expectations.

Despite being significantly lower than the 200% rate threatened by Trump, the deal is set to ramp up drug costs by billions.

A new report compiles the latest data and insight on scaling cell and gene therapy (CGT) effectively to improve patient access.

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation.

MetrioPharm’s lead compound, MP1032, has received ODD from the European Medicines Agency (EMA) for treating DMD in children.

ViroCell Biologics has partnered AvenCell Therapeutics for development of new allogeneic CAR-T therapies to treat blood cancers.

GSK's Q2 results show that sales of its specialist oncology assets have risen by 42%, while general drug sales were down 6%.

Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.